Use method of KV7 channel activator
By using Kv7.2 and Kv7.3 channel activators to regulate the function of KCNQ2 and KCNQ3 channels, the problem of difficulty in treating a variety of neurodevelopmental disorders and epileptic encephalopathy in the prior art has been solved, and effective treatment and symptom improvement of these diseases have been achieved.
Patent Information
- Application Number
- CN202410891759.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-09
- Filing Date
- 2020-09-17
- Publication Date
- 2024-11-22
AI Technical Summary
Current technologies are insufficient to effectively treat a variety of neurodevelopmental disorders and epileptic encephalopathy, especially those caused by dysfunction of the KCNQ2 and KCNQ3 channels, such as Angelman syndrome, neonatal withdrawal syndrome, and Dravet syndrome.
By using effective activators of Kv7.2 isotetramer, Kv7.3 isotetramer, and Kv7.2/7.3 heterotetramer, the function of KCNQ2 and KCNQ3 channels is regulated and cellular electrical balance is restored by administering therapeutically effective amounts of compound A or its pharmaceutically acceptable salts.
It effectively treats a variety of neurodevelopmental disorders and epileptic encephalopathy, including Angelman syndrome, neonatal withdrawal syndrome, and Dravet syndrome, restoring the electrophysiological balance of cells, reducing epileptic seizures, and improving the symptoms of neurodevelopmental disorders.
Smart Images

Figure CN118986972A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 202080079314.9, invention name “Method for using KV7 channel activators” and application date September 17, 2020 (PCT application number PCT / US2020 / 051171).
[0002] CROSS REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 901,621, filed September 17, 2019, and U.S. Provisional Application No. 62 / 945,300, filed December 9, 2019, which are incorporated herein by reference in their entireties.
[0004] Government Investment
[0005] This invention was made with U.S. Government support under Grant No. U44NS093160 awarded by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. The U.S. Government has certain rights in this invention. Summary of the invention
[0006] Embodiments described herein relate to methods for treating a neurodevelopmental disease or disorder, comprising administering to a pediatric subject in need thereof a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof. In certain embodiments, the subject is a fetus, a newborn from birth to about 1 month, an infant from about 1 month to about 24 months, a child from about 2 years to about 11 years, or an adolescent from about 12 years to about 18 years.
[0007] Embodiments described herein relate to methods for treating a neurodevelopmental disease or disorder, the method comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, which is selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide Methylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1-cyclobutyl)-3,3-dimethylbutyramide butyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide.
[0008] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder (NDD) comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the neurodevelopmental disease or disorder (NDD) is selected from Angelman syndrome, neonatal abstinence syndrome, early myoclonic encephalopathy, Landau Kleffner syndrome, electrical status epilepticus during sleep, Ohtahara syndrome, autism spectrum disorder, Dravet syndrome, Lennox–Gastaut syndrome, Rett syndrome, infantile spasms (West syndrome), SCN8A-associated epilepsy with encephalopathy (EIEE13), infantile epilepsy with metastatic focal epilepsy (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Doose syndrome, adrenoleukodystrophy (ALD), ATP6V1A encephalopathy, atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant ADRESD, CDKL5 encephalopathy, childhood epilepsy with centrotemporal spikes (CECTS), epileptic encephalopathy with continuous spikes during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, neuronal ceroid lipofuscinosis (NCL), nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, tuberous sclerosis (TS) / tuberous sclerosis complex (TSC), and combinations thereof.
[0009] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder (NDD) comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the neurodevelopmental disease or disorder (NDD) is selected from Angelman syndrome, neonatal abstinence syndrome, early myoclonic encephalopathy, Landau Kleffner syndrome, electrical status epilepticus during sleep, Ohtahara syndrome, autism spectrum disorder, Dravet syndrome, Lennox–Gastaut syndrome, Rett syndrome, infantile spasms (West syndrome), SCN8A-related epilepsy with encephalopathy (EIEE13), infantile epilepsy with metastatic focal epilepsy (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), and combinations thereof.
[0010] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder (NDD) comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the neurodevelopmental disease or disorder (NDD) is Doose syndrome.
[0011] Embodiments described herein relate to methods for treating a neurodevelopmental disease or disorder (NDD), comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the neurodevelopmental disease or disorder (NDD) is selected from adrenoleukodystrophy (ALD), ATP6V1A encephalopathy, atypical childhood epilepsy with central temporal spikes (ACECTS), autosomal dominant Lorenz epilepsy with speech dyspraxia (ADRESD), CDKL5 encephalopathy, childhood epilepsy with central temporal spikes (CECTS), epileptic encephalopathy with sleep moderate continuous spike-wave syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, neuronal ceroid lipofuscinosis (NCL), nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, tuberous sclerosis (TS) / tuberous sclerosis complex (TSC), and combinations thereof.
[0012] The embodiments described herein relate to a method for treating a developmental and epileptic encephalopathy (DEE), the method comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the developmental and epileptic encephalopathy (DEE) is selected from autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Dravet syndrome, early myoclonic encephalopathy, electrical status epilepticus during sleep (ESES), infantile epilepsy with focal epilepsy (EIMFS), Landau syndrome, Kleffner syndrome, Lennox–Gastaut syndrome, Ohtahara syndrome, SCN8A-related epilepsy with encephalopathy (EIEE13), infantile spasms (West syndrome), Doose syndrome, ATP6V1A encephalopathy, autosomal dominant Rolland epilepsy with dyspraxia of speech (ADRESD), CDKL5 encephalopathy, epileptic encephalopathy with continuous spikes during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, and combinations thereof.
[0013] Embodiments described herein relate to a method for treating developmental and epileptic encephalopathy (DEE), comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the developmental and epileptic encephalopathy (DEE) is selected from autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Dravet syndrome, early myoclonic encephalopathy, electrical status epilepticus during sleep (ESES), infantile epilepsy with focal epilepsy (EIMFS), Landau Kleffner syndrome, Lennox–Gastaut syndrome, Ohtahara syndrome, SCN8A-associated epilepsy with encephalopathy (EIEE13), infantile spasms (West syndrome), and combinations thereof.
[0014] Embodiments described herein relate to methods of treating developmental and epileptic encephalopathy (DEE) comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the developmental and epileptic encephalopathy (DEE) is Doose syndrome.
[0015] Embodiments described herein relate to methods for treating developmental and epileptic encephalopathy (DEE), comprising administering a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, wherein the developmental and epileptic encephalopathy (DEE) is selected from ATP6V1A encephalopathy, autosomal dominant Lorenz epilepsy with speech dyspraxia (ADRESD), CDKL5 encephalopathy, epileptic encephalopathy with continuous spikes and waves during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, non-syndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, and combinations thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 It was confirmed that compound A had a stronger negative shift in the activation voltage dependence of KCNQ2 homomers than that of KCNQ2 / Q3 heteromers and KCNQ3 homomers.
[0017] Figure 2 It was confirmed that compound A activated KCNQ2 homomers.
[0018] Figure 3 The membrane folding patterns of KCNQ2 subunits are depicted, showing the locations of some common pathogenic KCNQ2 EE variants.
[0019] Figure 4 It was demonstrated that in wild-type KCNQ2, at -40 mV, Compound A (0.3 μM and 1.0 μM) increased the homomeric channel density.
[0020] Figure 5 It was confirmed that compound A shifted the homomeric KCNQ2 G / V curve to the left, wherein solid circles represent wild-type KCNQ2, open circles represent wild-type KCNQ2 in the presence of 0.3 μM compound A, and solid triangles represent wild-type KCNQ2 in the presence of 1.0 μM compound A.
[0021] Figure 6 Depicted are the half-activation voltages (mV) of homomeric wild-type KCNQ2 and homomeric wild-type KCNQ2 with Compound A (0.3 μM and 1.0 μM).
[0022] Figure 7 Currents recorded from cells expressing heteromeric wild-type KCNQ2 / wild-type KCNQ3 channels before and during application of 1.0 μM Compound A are depicted.
[0023] Figure 8It was confirmed that compound A shifted the heteromeric KCNQ2 / wild-type KCNQ3 G / V curve to the left, wherein solid circles represent wild-type KCNQ2 / wild-type KCNQ3, open circles represent wild-type KCNQ2 / wild-type KCNQ3 in the presence of 1.0 μM compound A, and solid triangles represent wild-type KCNQ2 / wild-type KCNQ3 in the presence of 3.0 μM compound A.
[0024] Fig. 9 Depicted are the half-activation voltages (mV) of heteromeric wild-type KCNQ2 / KCNQ3 and heteromeric wild-type KCNQ2 / wild-type KCNQ3 channels in the presence of Compound A (1.0 μM and 3.0 μM).
[0025] Fig.10 Depicted are traces recorded at -40 mV from cells expressing wild-type KCNQ2 when treated with 3.0 μM Compound A, 10.0 μM ezogabine, and 10.0 μM ICA-069679 (ICA).
[0026] Fig.11 Depicted are current densities of wild-type KCNQ2 channels following treatment with 10.0 μM ezogabine, 3.0 μM Compound A, and 10.0 μM IC A.
[0027] Fig.12 The effects of Compound A and EZO on the KCNQ2 G / V curve are depicted, where solid circles represent wild-type KCNQ2, open circles represent wild-type KCNQ2 in the presence of 3.0 μM Compound A, and solid triangles represent wild-type KCNQ2 in the presence of 10.0 μM EZO.
[0028] Fig.13 Depicted are traces recorded at -40 mV from cells expressing KCNQ2 W236L when treated with 3.0 μM Compound A, 10.0 μM ezogabine, and 10.0 μM ICA-069679 (ICA).
[0029] Fig.14 Depicted are the current densities of KCNQ2W236L channels after treatment with 10.0 μM ezogabine, 3.0 μM Compound A, and 10.0 μM IC A.
[0030] Fig.15The effects of Compound A and EZO on the G / V curve of KCNQ2 W236L are depicted, wherein solid circles represent KCNQ2 W236L, open circles represent KCNQ2 W236L in the presence of 3.0 μM Compound A, solid triangles represent KCNQ2 W236L in the presence of 10.0 μM EZO, and open triangles represent KCNQ2 W236L in the presence of 10.0 μM ICA.
[0031] Fig.16 Depicted are the half-activation voltages (mV) of wild-type KCNQ2 / wild-type KCNQ2 with 3.0 μM Compound A and wild-type KCNQ2 / wild-type KCNQ2 with 10.0 μM EZO.
[0032] Fig.17 Depicted are the half-activation voltages (mV) of KCNQ2 W236L, KCNQ2 W236L with 3.0 μM Compound A, KCNQ2 W236L / KCNQ2 W236L with 10.0 μM EZO, and KCNQ2 W236L / KCNQ2 W236L with 10.0 μM ICA.
[0033] Fig.18 Currents recorded from cells expressing homomeric R210H channels before and during application of 1.0 μM Compound A are depicted.
[0034] Fig.19 The average current at +20 mV before and during treatment with Compound A is depicted.
[0035] Fig. 20 Depicted is a comparison of the effect of Compound A on wild-type KCNQ2 and 1:1 co-expressed wild-type KCNQ2 and R210H at -40 mV.
[0036] Fig.21 Depicted are the V of channels carrying different subunit combinations after application of compound A. 1 / 2 Overview of migration, where solid circles represent wild-type KCNQ2, open circles represent wild-type KCNQ2 in the presence of 1.0 μM Compound A, solid triangles represent wild-type KCNQ2 / R210H, open triangles represent wild-type KCNQ2 / R210H in the presence of 1.0 μM Compound A, solid squares represent R210H, and open squares represent R210H in the presence of 1.0 μM Compound A.
[0037] Fig. 22 The half-activation voltage (mV) of wild-type KCNQ2, wild-type KCNQ2 / R210H, and R210H when 1.0 μM Compound A was used is depicted.
[0038] Fig.23 Depicted are traces recorded at -40 mV from cells expressing wild-type KCNQ2 and cells expressing 1:1 KCNQ2 and KCNQ2 A294V before and during application of 0.3 μM Compound A.
[0039] Fig.24 Depicted are the effects of 0.3 μM Compound A on the current density of wild-type KCNQ2 channels and channels formed by 1:1 co-expression of wild-type KCNQ2 with R581L, T274M, and A294V, respectively.
[0040] Fig.25 Current density of wild-type KCNQ2 / A294V / wild-type KCNQ3 (ratio 1:1:2) and wild-type KCNQ2 / wild-type KCNQ3 heteromeric channels after treatment with 1.0 μM Compound A are depicted.
[0041] Fig.26 Depicted are the V of channels carrying different subunit combinations after application of compound A. 1 / 2 Overview of migration, where solid circles represent wild-type KCNQ2 / wild-type KCNQ3, open circles represent wild-type KCNQ2 / wild-type KCNQ3 in the presence of 1.0 μM Compound A, solid triangles represent wild-type KCNQ2 / A294V / wild-type KCNQ3 (ratio 1:1:2), and open triangles represent wild-type KCNQ2 / A294V / wild-type KCNQ3 in the presence of 1.0 μM Compound A (ratio 1:1:2).
[0042] Fig. 27 The half-activation voltage (mV) of wild-type KCNQ2 / wild-type KCNQ3 and wild-type KCNQ2 / A294V / wild-type KCNQ3 (ratio 1:1:2) when 1.0 μM Compound A was used is depicted.
[0043] Fig.28 Current density of wild-type KCNQ2 / T274M / wild-type KCNQ3 (ratio 1:1:2) and wild-type KCNQ2 / wild-type KCNQ3 heteromeric channels after treatment with 1.0 μM Compound A are depicted.
[0044] Fig.29 Depicted are the V of channels carrying different subunit combinations after application of compound A. 1 / 2Overview of migration, where solid circles represent wild-type KCNQ2 / wild-type KCNQ3, open circles represent wild-type KCNQ2 / wild-type KCNQ3 in the presence of 1.0 μM Compound A, solid triangles represent wild-type KCNQ2 / T274M / wild-type KCNQ3 (ratio 1:1:2), and open triangles represent wild-type KCNQ2 / T274M / wild-type KCNQ3 in the presence of 1.0 μM Compound A (ratio 1:1:2).
[0045] Fig.30 The half-activation voltage (mV) of wild-type KCNQ2 / wild-type KCNQ3 and wild-type KCNQ2 / T274M / wild-type KCNQ3 (ratio 1:1:2) when 1.0 μM Compound A was used is depicted. Detailed Description
[0046] Potassium (K) is present on the plasma membrane of most cell types. + ) channels are the most diverse class of all ion channels and are associated with a wide range of physiological functions including the regulation of electrical properties of excitable cells. The major pore-forming (α) subunits of these highly selective cation channels are divided into three primary structural classes based on the number of transmembrane (TM) spanning and pore (P) regions: currently known as 6TM / 1P, 2TM / 1P, and 4TM / 2P K + The Kv7 gene (originally known as KCNQ, a name assigned by the HUGO Gene Nomenclature Committee (HGNC)) was designated by the International Union of Pharmacology (IUPHAR) as a voltage-gated K + A subfamily of Kv7 channels. The Kv7 subfamily consists of five homologous pore-forming α subunits, Kv7.1-7.5, which have voltage-gated K + The typical structure of the channel has 6 TM spanning regions (S1-S6) and intracellular N-terminal and C-terminal domains on both sides, the typical voltage sensor domain located in S4 contains alternating positively charged residues, and has a single P region between S5 and S6 of each subunit. The channel is formed as a tetramer of the main α subunit, which can be a homotetramer or a heterotetramer. Neurons are known to express Kv7 channels composed of Kv7.2-7.5α subunits. Some of these gene products may appear exclusively in neurons, while other gene products, such as Kv7.4 and Kv7.5, can be found in other tissues such as smooth muscle and skeletal muscle.
[0047] Native M-currents were first characterized in amphibian sympathetic neurons. M-currents are notable because they are slowly activating and do not inactivate, are active at membrane potentials at or near the resting membrane potential of the neuron, and are reduced by muscarinic cholinergic agonists, confirming the association of G protein-coupled receptors (GPCRs) with physiological K.+ It was not until the cloning of this subfamily of genes that the pharmacological and biophysical properties of the Kv7.2 / 7.3 (and possibly Kv7.3 / 7.5) heteromultimers and the 'M'-currents were established, providing important new evidence for their importance in neuronal regulation.
[0048] The regional and developmental distribution of these channels, as well as their biophysical properties, support their role in providing a persistent resistance to the excitatory influence of depolarization. Under physiological conditions, they can very effectively modulate the subthreshold excitability of certain neuronal populations, as demonstrated using native M-currents, and in many types of neurons they have an important role in regulating the frequency and ultimately the pattern of action potential firing. The discovery that neuronal Kv7 mutations cause benign familial neonatal convulsions (BFNC) highlights their importance in neuronal regulation, indicating that reducing the effects of Kv7.2 and Kv7.3 channels can significantly alter neuronal excitability. Mutational analysis confirms their involvement in BFNC and suggests that they could be used as targets for antiepileptic drugs (AEDs).
[0049] It is reported that mutations in Kv7.2 and less common Kv7.3 are the cause of autosomal dominant benign neonatal epilepsy (BFNS), mainly caused by haploinsufficiency. BFNS is an idiopathic epilepsy in which epileptic seizures occur in the first few days of life, caused by mutations in both Kv7.2 and Kv7.3. Kv7.2 and Kv7.3 interact to produce a larger current than a single current obtained as a homopolymer. In situ hybridization shows that Kv7.2 is mainly present in the cerebellar cortex, neocortex and hippocampal structures including the dentate gyrus. These three structures present different susceptibility to epileptic seizures. In the mouse brain, Kv7.3 is located in the same region. However, the appearance of Kv7.2 expression is earlier than Kv7.3, and it is rapidly increased in the first week of life. At birth, Kv7.3 is expressed in very low amounts, while Kv7.2 is already expressed at significant levels. Therefore, different association profiles occur between Kv7.2 and Kv7.3 during development.
[0050] Although BFNS generally has an excellent long-term prognosis, recurrences of epilepsy later in life have also been described. De novo dominant-negative mutations in the KCNQ2 gene have recently been found to cause a rare and devastating pediatric epileptic encephalopathy, KCNQ2 epileptic encephalopathy (KCNQ2-EE), which accounts for 5% to 23% of early infantile epileptic encephalopathy (EIEE). Although only recently described, heterozygous de novo variants of KCNQ2 are highly recognized causes of early-onset epileptic encephalopathy, and KCNQ2-EE has become a well-defined clinical entity with characteristic neonatal presentations, including hypotonia, refractory tonic seizures, severely abnormal interictal EEG with marked burst suppression, and most often with moderate to severe global developmental delay caused by identified missense variants in a portion of the gene. In some cases, neuroimaging reveals frontal hypoplasia or transient MRI signal abnormalities in the basal ganglia or thalamus. Neurodevelopment is negatively affected in all children, even if seizure control is achieved with AEDs in the first few months of life. It has been proposed that the clinical features of KCNQ2-EE may be related to the functional consequences of the mutation on the M-current and thus predict neurological prognosis. It is known that KCNQ2 mutations have markedly different effects on Kv7.2 channel function, which vary with binding to the Kv7.3 subunit. The density of homomeric channels may be the most reliable property linking Kv7.2 function to encephalopathy. It is hypothesized that homomeric Kv7.2 channels play a critical role in fine-tuning neuronal connections during early brain development and correlate with the severity of the dominant-negative effects of KCNQ2 mutations that cause encephalopathy.
[0051] The compounds provided herein are potent activators of Kv7.2 homotetramers, Kv7.3 homotetramers, and Kv7.2 / 7.3 heterotetramers, and based on the expression of the above-mentioned Kv7.2 and Kv7.3 channels, such compounds are effective in treating early infant development disorders, neurodevelopmental diseases or disorders (NDDs), and developmental and epileptic encephalopathy (DEE), such as Angelman syndrome, neonatal abstinence syndrome, early myoclonic encephalopathy, Landau Kleffner syndrome, electrical status epilepticus during sleep, Ohtahara syndrome, autism spectrum disorder, Dravet syndrome, Lennox–Gastaut syndrome, Rett syndrome, infantile spasms (West syndrome), SCN8A-related epilepsy with encephalopathy (EIEE13), infantile epilepsy with focal epilepsy (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Doose syndrome, adrenoleukodystrophy (ALD), ATP6V1A encephalopathy, atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant ADRESD, CDKL5 encephalopathy, childhood epilepsy with centrotemporal spikes (CECTS), epileptic encephalopathy with continuous spikes during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, neuronal ceroid lipofuscinosis (NCL), nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, tuberous sclerosis (TS) / tuberous sclerosis complex (TSC), and combinations thereof.
[0052] Before describing the compositions and methods of the present invention, it should be understood that any invention is not limited to the specific processes, compositions or methods described, as they may vary. In addition, the processes, compositions and methods described in specific embodiments are interchangeable. Thus, for example, the compositions, dosing regimens, routes of administration, etc. described in specific embodiments can be used in any method described in other specific embodiments. It should also be understood that the terms used in the description are only for the purpose of describing a specific version or embodiment, and are not intended to limit the scope of the present invention, which will be limited only by the appended claims. Unless otherwise expressly defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art. Although any method similar or equivalent to that described herein can be used in the practice or testing of embodiments of the present invention, preferred methods are now described. All publications and references mentioned herein are incorporated herein by reference. Nothing herein should be construed as admitting that the present invention has no right to be disclosed earlier than such disclosure by virtue of prior invention.
[0053] It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0054] When used in this article, the term "about" means plus or minus 10% of the numerical value of the number used therewith. Therefore, about 50% means within the range of 45%-55%. Unless otherwise stated, all numbers used in this specification and claims to represent the amount of components, properties such as molecular weight, reaction conditions, etc. should be understood to be modified by the term "about" in all cases. Therefore, unless otherwise stated, the numerical parameters proposed in this specification and the accompanying claims are approximate values, which may change with the desired properties attempted to be obtained. At least and not attempting to limit the application of the principle of equivalents to the scope of the claims, each numerical parameter should at least be interpreted according to the number of reported significant figures and by applying ordinary rounding techniques.
[0055] When used in conjunction with a therapeutic agent, "administration" means administering the therapeutic agent directly into or onto a target tissue or administering the therapeutic agent to a subject, whereby the therapeutic agent has a positive effect on the tissue to which it is targeted. "Administration" of a composition can be achieved by oral administration, injection, infusion, absorption, or by any method combined with other known techniques. "Administration" can include the act of self-administration or administration by another person, such as a healthcare provider or device.
[0056] As used herein, the term "comprising" is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
[0057] As used herein, the term "consisting of" means that the composition or method includes only those elements, steps or ingredients specifically listed in the particular embodiment or claim.
[0058] As used herein, the term "consisting essentially of means that the composition or method includes only the specified materials or steps and those materials or steps that do not materially affect the basic and novel characteristics of the claimed invention.
[0059] The term "improvement" is used to convey that the present invention refers to the overall physical condition of an individual to whom an active agent has been administered. For example, if one or more symptoms of a condition, disease, or disorder, such as epilepsy or a neurodegenerative disorder, are alleviated by administration of an active agent, the overall physical condition of the individual may be "improved." "Improvement" may also refer to a change in the appearance, form, characteristics, and / or physical properties, or any combination thereof, of a tissue to which an active agent is provided, applied, or administered.
[0060] The terms "inhibit," "suppress," "reduce," "interfere with," and / or "reduce" (and similar terms) generally refer to an action that directly or indirectly decreases a function, activity, or behavior relative to a natural, expected, or average value, or relative to current conditions.
[0061] The term "homomer" or "homototramer" is used to refer to a configuration of Kv7 channels in which all four subunits are of the same type, either wild type, mutant, or any combination thereof. For example, a KCNQ2 homomer or a Kv7.2 homomer consists of four α subunits of Kv7.2.
[0062] The terms "heteromer" or "heterotetramer" are used interchangeably and are used to refer to a configuration of Kv7 channels in which the four subunits have two or more subtypes, which can be wild-type, mutant, or any combination thereof. For example, the KCNQ2 / 3 heteromer or Kv7.2 / Kv7.3 heteromer consists of a mixed combination of Kv7.2 and Kv7.3 subunits.
[0063] In each of the embodiments disclosed herein, the compositions and methods can be used for subjects in need of such treatment, which may also be referred to as "in need thereof." As used herein, the phrase "in need thereof" means that a subject has been identified as being in need of a particular method or treatment, and that the treatment has been provided to the subject for that specific purpose.
[0064] As used herein, the term "therapeutic agent" means an agent that is used for the treatment, counteracting, amelioration or prevention, or any combination thereof, of an unwanted condition, disorder or disease in a subject.
[0065] When used herein, the terms "patient" and "subject" are interchangeable and can be used to refer to any living organism that can be treated with the compounds of the present invention. Therefore, the terms "patient" and "subject" can include, but are not limited to, any non-human mammal, primate, or human. In certain embodiments, the "patient" or "subject" is an adult, child, infant, or fetus. In certain embodiments, the "patient" or "subject" is a human. In certain embodiments, the "patient" or "subject" is a mammal, such as a mouse, rat, other rodent, rabbit, dog, cat, pig, cattle, sheep, horse, primate, or human. In certain embodiments, the human is a newborn from birth to about 1 month. In certain embodiments, the human is an infant from about 1 month to about 24 months. In certain embodiments, the human is a fetus and is treated in the womb. In certain embodiments, the human is a child from about 2 years old to about 11 years old. In certain embodiments, the human is an adolescent from about 12 years old to 18 years old. In embodiments, the subject is a pediatric subject, which is a human fetus (treated in utero), a newborn from birth to about 1 month, an infant from about 1 month to about 24 months, a child from about 2 years to about 11 years, or an adolescent from about 12 years to 18 years.
[0066] As used herein, the terms "therapeutically effective amount" or "therapeutic dose" are interchangeable and may refer to the amount of an active agent or pharmaceutical compound or composition that elicits a clinical, biological, or medical response in a tissue, system, animal, individual, or human that is being sought by a researcher, veterinarian, physician, or other clinical professional. A clinical, biological, or medical response may include, for example, one or more of the following: (1) preventing a disease, condition, or disorder in an individual who may be susceptible to the disease, condition, or disorder but who does not yet experience or exhibit the pathology or symptoms of the disease, condition, or disorder, (2) inhibiting the disease, condition, or disorder or halting further development of the disease, condition, or disorder pathology and / or symptoms in an individual who is experiencing or exhibiting the disease, condition, or disorder pathology or symptoms, and (3) ameliorating the disease, condition, or disorder or reversing the pathology and / or symptoms experienced or exhibited by the individual who is experiencing or exhibiting the disease, condition, or disorder pathology or symptoms.
[0067] The term "treatment" can be used to mean the prevention of a specific disorder, disease or condition, the alleviation of symptoms associated with a specific disorder, disease or condition, and / or the prevention of symptoms associated with a specific disorder, disease or condition. In certain embodiments, the term refers to slowing down the progression of the disorder, disease or condition or alleviating symptoms associated with the specific disorder, disease or condition. In certain embodiments, the term refers to alleviating symptoms associated with the specific disorder, disease or condition. In certain embodiments, the term refers to alleviating symptoms associated with the specific disorder, disease or condition. In certain embodiments, the term refers to restoring a function that is damaged or lost due to a specific disorder, disease or condition.
[0068] "Pharmaceutically acceptable salts" means salts which are suitable for use in contact with patient tissues without excessive toxicity, irritation, allergic reaction, etc., within the scope of sound medical judgment, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., (1977) J. Pharm. Sciences, Vol. 6, 1-19, describe pharmaceutically acceptable salts in detail. Pharmaceutically acceptable "salts" are any acid addition salts, preferably pharmaceutically acceptable acid addition salts, including but not limited to hydrohalide salts, such as hydrobromide, hydrochloride, hydrofluoride and hydroiodide; inorganic acid salts, such as nitrate, perchlorate, sulfate and phosphate; organic acid salts, such as sulfonate (methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate or p-toluenesulfonate), acetate, malate, fumarate, succinate, citrate, benzoate, gluconate, lactate, mandelate, mucate, pamoate, pantothenate, oxalate and maleate; and amino acid salts, such as aspartate or glutamate. The acid addition salt can be a monoacid or diacid addition salt, such as a dihydrohalide, disulfate, diphosphate or diorganic acid salt. In all cases, the acid addition salt is used as an achiral reagent, which is not selected based on any expected or known preference for interaction or precipitation with a particular optical isomer of the disclosed product.
[0069] If no stereochemistry is indicated, the name or structural description includes any stereoisomer or any mixture of stereoisomers, and Applicants reserve the right to specifically identify and claim a compound as a single stereoisomer or any particular mixture of stereoisomers.
[0070] The compounds described herein may contain asymmetric centers and may therefore exist as enantiomers. In the case where the compounds described in accordance with the embodiments herein have two or more asymmetric centers, they may additionally exist as diastereomers. The embodiments herein include all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, and mixtures of diastereomers. In certain embodiments, the structural formula shown does not have clear stereochemistry at certain positions. The embodiments herein include all stereoisomers of such structural formulas and pharmaceutically acceptable salts thereof. The diastereoisomer pairs of enantiomers can be separated, for example, by fractional crystallization from a suitable solvent, and the enantiomer pairs thus obtained can be separated into individual stereoisomers by conventional means, for example, by using optically active acids or bases as resolving agents or by separation on chiral HPLC columns. In addition, any enantiomer or diastereomer of the compound of the general formula can be obtained by stereospecific or stereoselective synthesis using optically pure or enantiomerically enriched starting materials or reagents of known configuration. The embodiments described and claimed herein encompass within their scope the racemic forms as well as individual enantiomers, diastereomers, and stereoisomerically enriched mixtures of the compounds, and Applicants reserve the right to specifically identify and claim compounds in any such forms.
[0071] The compounds disclosed herein may exist as stereoisomers, conformational isomers, mixtures thereof in all ratios, and isotopic forms, such as deuterated compounds, and therefore include all such forms, and the applicant reserves the right to specifically identify and claim compounds in any such form.
[0072] Compound
[0073] Embodiments described herein involve the use of any of the following compounds or a pharmaceutically acceptable salt thereof: N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N -(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(7-cyano -1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-cyclobutyl-7-(trifluorobutyl)-1-cyclobutyl-2-yl)-3,3-dimethylbutanamide The results for these compounds can be found in Table 1. In embodiments, such compounds can be administered in a pharmaceutical composition described herein.
[0074] Table 1: Compound structures
[0075]
[0076]
[0077]
[0078] How to use
[0079] Embodiments described herein relate to methods of treating a disease or disorder that would benefit from activation of a Kv7.2 homomer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropane)-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1-hydroxy-1 -2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide 2-yl)-3,3-dimethylbutanamide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide In some embodiments, the disease or disorder is developmental and is diagnosed during the prenatal period, neonatal period, infancy, early childhood, adolescence, and early adulthood. In some embodiments, the human subject is diagnosed before birth. In certain embodiments, a neonate is diagnosed at about birth to about 1 week or about 1 week to about 1 month. In certain embodiments, an infant is diagnosed at about birth to about 1 week, about 1 week to about 1 month, about 1 month to about 24 months.In certain embodiments, the child is diagnosed at about birth to about 1 week, about 1 week to about 1 month, about 1 month to about 24 months, about 2 years to about 11 years. In certain embodiments, the subject is a newborn baby from about birth to about 1 month. In certain embodiments, the subject is an infant from about 1 month to about 24 months. In certain embodiments, the subject is a fetus and is treated in utero. In certain embodiments, the subject is a child from about 2 years to about 11 years. In certain embodiments, the subject is a teenager from about 12 years to 18 years. In certain embodiments, the subject is a pediatric subject.
[0080] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H- N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 -cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the disease or disorder occurs early in life between about 0 days to about 1 year. The brains of newborns and infants are undergoing changes early in development and are more susceptible to change during this sensitive period. Studies in rodents have shown that KCNQ2 expression is dominant over KCNQ3 early in life. Delayed expression of KCNQ3 results in a greater density of KCNQ2 homomers relative to KCNQ2 / KCNQ3 heteromers.In embodiments described herein, the methods of treating a developmental disease or disorder are effective to restore electrical balance to the cell or normalize overexcitation caused by a gene or mechanism associated with KCNQ2. In embodiments, the subject is a pediatric subject.
[0081] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H- N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 -cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the subject is a pediatric subject.In certain embodiments, the neurodevelopmental disease or disorder is selected from Angelman syndrome, neonatal abstinence syndrome, early myoclonic encephalopathy, Landau Kleffner syndrome, electrical status epilepticus during sleep, Ohtahara syndrome, autism spectrum disorder, Dravet syndrome, Lennox–Gastaut syndrome, Rett syndrome, infantile spasms (West syndrome), SCN8A-related epilepsy with encephalopathy (EIEE13), infantile epilepsy with metastatic focal epilepsy (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Doose syndrome, adrenoleukodystrophy (ALD), ATP6V1A encephalopathy, atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant ADRESD, CDKL5 encephalopathy, childhood epilepsy with centrotemporal spikes (CECTS), epileptic encephalopathy with continuous spikes during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, neuronal ceroid lipofuscinosis (NCL), nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, tuberous sclerosis (TS) / tuberous sclerosis complex (TSC), and combinations thereof.
[0082] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H- N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 -cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the subject is a pediatric subject.In certain embodiments, the neurodevelopmental disease or disorder is selected from Angelman syndrome, neonatal abstinence syndrome, early myoclonic encephalopathy, Landau Kleffner syndrome, electrical status epilepticus during sleep, Ohtahara syndrome, autism spectrum disorder, Dravet syndrome, Lennox–Gastaut syndrome, Rett syndrome, infantile spasms (West syndrome), SCN8A-related epilepsy with encephalopathy (EIEE13), infantile epilepsy with metastatic focal epilepsy (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), and combinations thereof.
[0083] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H- N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 -cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In certain embodiments, the neurodevelopmental disease or disorder is Doose syndrome. In embodiments, the subject is a pediatric subject.
[0084] Embodiments described herein relate to methods of treating a neurodevelopmental disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H- N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 -cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the subject is a pediatric subject.In certain embodiments, the neurodevelopmental disease or disorder is selected from adrenoleukodystrophy (ALD), ATP6V1A encephalopathy, atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant Loran's epilepsy with dyspraxia of speech (ADRESD), CDKL5 encephalopathy, childhood epilepsy with centrotemporal spikes (CECTS), epileptic encephalopathy with continuous spikes during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, neuronal ceroid lipofuscinosis (NCL), nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, tuberous sclerosis (TS) / tuberous sclerosis complex (TSC), and combinations thereof.
[0085] Embodiments described herein relate to methods of treating developmental and epileptic encephalopathy (DEE) comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide. -1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl) -3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the subject is a pediatric subject.In certain embodiments, the developmental and epileptic encephalopathy (DEE) is selected from autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Dravet syndrome, early myoclonic encephalopathy, electrical status epilepticus during sleep (ESES), infantile epilepsy with focal epilepsy (EIMFS), Landau syndrome, Kleffner syndrome, Lennox–Gastaut syndrome, Ohtahara syndrome, SCN8A-related epilepsy with encephalopathy (EIEE13), infantile spasms (West syndrome), Doose syndrome, ATP6V1A encephalopathy, autosomal dominant Rolland epilepsy with dyspraxia of speech (ADRESD), CDKL5 encephalopathy, epileptic encephalopathy with continuous spikes during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, and combinations thereof.
[0086] Embodiments described herein relate to methods of treating developmental and epileptic encephalopathy (DEE) comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide. -1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl) -3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the subject is a pediatric subject.In certain embodiments, the developmental and epileptic encephalopathy (DEE) is selected from autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Dravet syndrome, early myoclonic encephalopathy, electrical status epilepticus during sleep (ESES), infantile epilepsy with focal epilepsy (EIMFS), Landau Kleffner syndrome, Lennox–Gastaut syndrome, Ohtahara syndrome, SCN8A-associated epilepsy with encephalopathy (EIEE13), infantile spasms (West syndrome), and combinations thereof.
[0087] Embodiments described herein relate to methods of treating developmental and epileptic encephalopathy (DEE) comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)- oxazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(7-cyano -1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide )-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In certain embodiments, the developmental and epileptic encephalopathy (DEE) is Doose syndrome. In embodiments, the subject is a pediatric subject.
[0088] Embodiments described herein relate to methods of treating developmental and epileptic encephalopathy (DEE) comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide. -1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl) -3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the subject is a pediatric subject.In certain embodiments, the developmental and epileptic encephalopathy (DEE) is selected from ATP6V1A encephalopathy, autosomal dominant Rollan's epilepsy with speech dyspraxia (ADRESD), CDKL5 encephalopathy, epileptic encephalopathy with continuous spikes and waves during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, non-syndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, and combinations thereof.
[0089] Embodiments described herein relate to methods of treating Angelman syndrome, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; )-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide )-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. In embodiments, the subject is a pediatric subject. Angelman syndrome is caused by loss of function of the UBE3A gene, which plays a role in the normal development of the nervous system. Patients exhibit intellectual disability, abnormal gait, speech disorders, seizures, and inappropriately joyful behavior, including frequent laughter, smiling, and excitement. They are usually treated with anticonvulsants. The compounds described herein are effective in treating seizures associated with Angelman syndrome.
[0090] Embodiments described herein relate to methods of treating neonatal abstinence syndrome, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1- Cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. Neonatal abstinence syndrome occurs when infants are born dependent on drugs due to exposure in utero. At birth, they may experience withdrawal symptoms, including seizures. Withdrawal from opioids may result in changes in excitatory transmission. The compounds described herein reverse the excitability and improve withdrawal symptoms. In an embodiment, the subject is a pediatric subject.
[0091] Embodiments described herein relate to methods for treating early myoclonic encephalopathy, Landau Kleffner syndrome, and electrical status epilepticus during sleep, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H -benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 -cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. Early myoclonic encephalopathy is diagnosed in infants who present with seizures early in life and has multiple contributing factors. Seizures are resistant to standard treatments and the prognosis is poor. The compounds described herein are effective in treating early myoclonic encephalopathy.In an embodiment, the subject is a pediatric subject.
[0092] Embodiments described herein relate to methods of treating Ohtahara syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; )-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide )-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- Ohtahara syndrome (OS) or early infantile epileptic encephalopathy (EIEE) is a rare type of epilepsy that usually becomes apparent within the first 1-3 months of life. OS can be caused by brain malformations, metabolic disorders, and mutations in genes including KCNQ2. Infants primarily have tonic seizures but may also experience partial and, rarely, myoclonic seizures. Most infants with the disorder show significant maldevelopment of part or all of the cerebral hemispheres.The EEG of an infant with Ohtahara syndrome reveals a characteristic pattern of high-voltage spike discharges followed by almost no activity. This pattern is called "burst suppression". The course of Ohtahara syndrome is severely progressive. Seizures become more frequent, with delays in physical and cognitive development. Some children die in infancy; others survive but are severely disabled. As they grow, some children develop other epileptic disorders such as infantile spasms (West syndrome) or Lennox-Gestaut syndrome. Due to the early onset, Kv7 channel activators are an effective treatment option for this disease. In an embodiment, the subject is a pediatric subject.
[0093] Embodiments described herein relate to methods of treating autism spectrum disorders, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1- Cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. Several voltage-gated potassium channels have been implicated in patients with autism, including mutations and truncations in the KCNQ3 gene. Dysregulation of Kv7 function promotes seizures and impairs normal development, which may contribute to autistic phenotypes. Autism spectrum disorder (ASD) is a developmental disorder that affects communication and behavior. Although autism can be diagnosed at any age, it is called a "developmental disorder" because symptoms usually appear in the first two years of life.According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a guide created by the American Psychiatric Association for diagnosing mental disorders, people with ASD have the following characteristics: 1) difficulty communicating and interacting with others, 2) restricted interests and repetitive behaviors, and 3) symptoms that impair the individual's ability to function normally in school, work, and other areas of life. Autism is called a "spectrum" disorder because the type and severity of symptoms people experience vary greatly. The compounds described herein restore synaptic transmission required for normal development. In an embodiment, the subject is a pediatric subject.
[0094] Embodiments described herein relate to methods of treating Dravet syndrome, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H- N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 Mutations in the SCN1A gene, which encodes a voltage-gated sodium channel, are common in Dravet syndrome. The mutations result in decreased sodium currents, causing hyperexcitation of GABAergic inhibitory neurons, leading to epilepsy. KCNQ2 mutations have recently been shown to contribute to the clinical manifestations of Dravet syndrome. Dravet syndrome, formerly known as severe myoclonic epilepsy of infancy (SMEI), is a rare, intractable developmental epileptic encephalopathy with onset in infancy and significant neurodevelopmental, motor, cognitive, and behavioral consequences that persist into adulthood.Dravet syndrome is characterized by prolonged high fever and non-high fever seizures within the first year after birth. The disease progresses to other seizure types, such as myoclonic and partial seizures, psychomotor retardation and ataxia. It is characterized by cognitive impairment, behavioral disorders and motor deficits. Behavioral deficits typically include hyperactivity and impulsivity, and in rarer cases also include autism-like behaviors. As the patient ages, the seizures experienced by people with Dravet syndrome become worse. The compounds described herein are effective in Dravet syndrome by restoring the balance of excitation and inhibition in these neurons. In an embodiment, the subject is a pediatric subject.
[0095] Embodiments described herein relate to methods of treating Lennox–Gastaut syndrome, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro- 2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide imidazol-2-yl)-3,3-dimethylbutanamide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6- Cyano-1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. Lennox-Gastaut syndrome (LGS) is a severe, complex, and rare childhood-onset epilepsy with a multifactorial etiology. There is evidence that cortical excitability during development contributes to the disease. Changes in excitability may be secondary to brain damage. Symptoms of Lennox-Gastaut syndrome usually begin in infancy or childhood, more usually between 3 and 5 years of age.Affected children experience several different types of seizures, the most common being atonic, tonic, and atypical absence seizures. Tonic seizures cause an increase in muscle tone and muscle rigidity. They are characterized by sustained muscle contractions, which can cause minor abnormalities such as slight bending of the body and brief interruptions in breathing, or more significant problems such as spasms of facial muscles and bending or extension of arms and legs. Tonic seizures are usually brief (lasting a few seconds to a minute) and are particularly prevalent during sleep at night, but may also occur during the day. Atonic seizures cause a sudden loss of muscle tone and limp. They may cause the head to droop or nod, posture problems, or sudden falls. Atonic seizures are also called fall attacks. Atonic seizures may only partially affect consciousness, usually lasting only a few seconds. Atypical absence seizures are often accompanied by periods of unconsciousness characterized by unresponsive staring. Absence seizures usually start and end suddenly, and affected individuals usually resume activities without remembering the seizure. Absence seizures do not cause convulsions and may be so mild that they are not noticed. They usually last only a few seconds. Children with Lennox-Gastaut syndrome may also experience cognitive dysfunction, delays in reaching developmental milestones, and behavioral problems ranging from hyperactivity and irritability to autistic symptoms and psychosis. LGS has a poor prognosis, with a 5% mortality rate in childhood and persistent seizures in adulthood (80%-90%). Typically, diagnosis requires three findings: multiple generalized seizure types; a slow spike wave pattern (less than 2.5 Hz) on the EEG; and cognitive dysfunction. The compounds described herein normalize brain excitability, reduce seizures, and may improve developmental outcomes and reduce behavioral problems. In an embodiment, the subject is a pediatric subject.
[0096] Embodiments described herein relate to methods of treating Rett syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1 H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)- 3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 Rett syndrome is a rare, inherited neurological disorder that occurs primarily in girls. People with Rett syndrome appear normal early in life, but then have slow growth and development later in life and develop problems with walking, seizures, and intellectual disability. Many cases involve mutations in the MECP2 gene, which is thought to control the function of many other genes and disrupt the normal function of nerve cells. After clinical diagnosis, patients were found to have mutations in other genes, including KCNQ2.The compounds described herein are effective treatments for Rett syndrome.In an embodiment, the subject is a pediatric subject.
[0097] Embodiments described herein relate to methods of treating infantile spasms (West syndrome), the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl) -1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl) -3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. Infantile spasms (West syndrome) are characterized by epileptic spasms that occur early in life and intellectual disability. In many cases, infantile spasms also include hyperrhythmic dysrhythmias, chaotic and disorganized brain activity. The diagnosis is clinical and is a combination of myoclonic jerks, developmental regression, and characteristic EEG patterns. There are many potential causes including structural, metabolic, and genetic, which all produce epileptic seizure disorders. Due to the early onset of the disease, the compounds described herein are effective treatment options for the disease.In embodiments, the subject is a pediatric subject.
[0098] Embodiments described herein relate to methods for treating SCN8A-related epilepsy with encephalopathy (EIEE13), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylprop- 2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide -yl)-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano -1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. EIEE13 is characterized by recurrent seizures, abnormal brain function, and intellectual disability; symptoms begin in infancy. Seizures can occur as frequently as hundreds per day and are unresponsive to current anti-epileptic drugs. EIEE13 is caused by a mutation in the SCN8A gene that results in increased Nav1.6 function. Increased Nav1.6 activity results in increased excitation of neurons in the brain. The compounds described herein reduce brain excitability and restore normal brain function during a critical neurodevelopmental period.In embodiments, the subject is a pediatric subject.
[0099] Embodiments described herein relate to methods of treating infantile epilepsy with focal epilepsy of transference (EIMFS), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methyl N-(1-(tert-butyl)-6-(1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide 2-yl)-3,3-dimethylbutanamide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. Epilepsy of infancy with focal epilepsy of migration (EIMFS) is also known as infantile partial epilepsy of migration, infantile partial epilepsy of migration, and infantile malignant partial epilepsy of migration. EIMFS is a rare epilepsy syndrome in which seizures begin within the first few weeks of life. The seizures are focal but migrate to different parts of the brain. Autonomic changes (stopping breathing, turning blue, sweating, and hiccups) are often seen during seizures.EIMFS is associated with mutations in several genes, including the KCNT1 potassium channel, which accounts for 40% of EIMFS cases. The KCNT1 channel contributes to resting membrane potential and neuronal firing. The compounds described herein are effective in treating EIMFS. In an embodiment, the subject is a pediatric subject.
[0100] Embodiments described herein relate to methods of treating autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methyl N-(1-(tert-butyl)-6-(1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide -2-yl)-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide ADNFLE is a rare form of epilepsy that begins in early childhood. Seizures usually occur at night while the patient is asleep. Seizures tend to occur in clusters and may occur with sudden, repetitive movements and vocalizations. ADNFLE is caused by mutations in the gene that encodes the nicotinic acetylcholine receptor, which plays an important role in signaling between nerve cells and the brain. Disruption of neuronal networks is associated with epileptic seizures. Kv7 activation during this critical developmental period can restore normal brain function and prevent epileptic seizures.The compounds described herein are effective in treating ADNFLE. In an embodiment, the subject is a pediatric subject.
[0101] Embodiments described herein relate to methods of treating Doose syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1 H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)- 3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 Doose syndrome, also known as myoclonic static epilepsy (MAE), is an early childhood epilepsy syndrome that more commonly affects boys than girls, with onset usually between 2 and 6 years of age. Children with Doose syndrome develop a variety of seizure types, including drop attacks. About one-third of children may have episodes of nonconvulsive status epilepticus. Childhood development is usually normal before the onset of seizures. With frequent seizures, development slows and may regress.The compounds described herein are effective in treating Doose syndrome. In an embodiment, the subject is a pediatric subject.
[0102] Embodiments described herein relate to methods for treating adrenoleukodystrophy (ALD). The methods include administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide. N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-( 7-Cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-cyclobutyl-7- (Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating adrenoleukodystrophy (ALD). In embodiments, the subject is a pediatric subject.
[0103] Embodiments described herein relate to methods of treating ATP6V1A encephalopathy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H- N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3 ,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1 -cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating ATP6V1A encephalopathy. In embodiments, the subject is a pediatric subject.
[0104] Embodiments described herein relate to methods of treating atypical childhood epilepsy with centrotemporal spikes (ACECTS), the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2- methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide oxazol-2-yl)-3,3-dimethylbutanamide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6- Cyano-1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating atypical childhood epilepsy with centrotemporal spikes (ACECTS). In embodiments, the subject is a pediatric subject.
[0105] Embodiments described herein relate to methods of treating autosomal dominant Loran's epilepsy with speech dyspraxia (ADRESD), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro -2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d ] imidazol-2-yl)-3,3-dimethylbutanamide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6 -cyano-1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating autosomal dominant Rolland's epilepsy with speech dyspraxia (ADRESD). In embodiments, the subject is a pediatric subject.
[0106] Embodiments described herein relate to methods of treating CDKL5 encephalopathy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1- Cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating CDKL5 encephalopathy. In embodiments, the subject is a pediatric subject.
[0107] Embodiments described herein relate to methods of treating childhood epilepsy with centrotemporal spikes (CECTS), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropane- 2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide -yl)-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano -1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating childhood epilepsy with central temporal spikes (CECTS). In embodiments, the subject is a pediatric subject.
[0108] Embodiments described herein relate to methods for treating epileptic encephalopathy with sustained spikes during sleep syndrome (ECSWS), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methyl N-(1-(tert-butyl)-6-(1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide -2-yl)-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating epileptic encephalopathy with continuous spikes and waves during sleep syndrome (ECSWS). In embodiments, the subject is a pediatric subject.
[0109] Embodiments described herein relate to methods of treating GRIN1 encephalopathy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1- Cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating GRIN1 encephalopathy. In an embodiment, the subject is a pediatric subject.
[0110] Embodiments described herein relate to methods of treating GRIN2A epilepsy-aphasia syndrome, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide. -1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl) -3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective for treating GRIN2A epilepsy-aphasia syndrome. In embodiments, the subject is a pediatric subject.
[0111] Embodiments described herein relate to methods of treating GRIN2B encephalopathy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1- Cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating GRIN2B encephalopathy. In embodiments, the subject is a pediatric subject.
[0112] Embodiments described herein relate to methods for treating moderate epilepsy-aphasia disorder (IEAD), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; )-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide )-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating moderate epilepsy-aphasia disorder (IEAD). In an embodiment, the subject is a pediatric subject.
[0113] Embodiments described herein relate to methods of treating infantile KCNT1 epilepsy with focal epilepsy of metastatic origin, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropane- 2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide -yl)-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano -1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective for treating infantile KCNT1 epilepsy with focal epilepsy of metastatic origin. In an embodiment, the subject is a pediatric subject.
[0114] Embodiments described herein relate to methods of treating neuronal ceroid lipofuscinosis (NCL), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; )-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide )-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating neuronal ceroid lipofuscinosis (NCL). In embodiments, the subject is a pediatric subject.
[0115] Embodiments described herein relate to methods of treating nonsyndromic developmental and epileptic encephalopathy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide. -1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl) -3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating non-syndromic developmental and epileptic encephalopathy. In embodiments, the subject is a pediatric subject.
[0116] Embodiments described herein relate to methods of treating PTPN23 encephalopathy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1- Cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating PTPN23 encephalopathy. In embodiments, the subject is a pediatric subject.
[0117] Embodiments described herein relate to methods of treating Rasmussen syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropane-2 -yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide -1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein may be effective in treating Rasmussen syndrome. In embodiments, the subject is a pediatric subject.
[0118] Embodiments described herein relate to methods for treating SCN2A-related neonatal epilepsy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)- 1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl) -3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano- 1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective for treating SCN2A-related neonatal epilepsy. In an embodiment, the subject is a pediatric subject.
[0119] Embodiments described herein relate to methods of treating STXBP1 encephalopathy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-1- Cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective in treating STXBP1 encephalopathy. In an embodiment, the subject is a pediatric subject.
[0120] Embodiments described herein relate to methods of treating tuberous sclerosis complex (TS) / tuberous sclerosis complex (TSC), the methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methyl N-(1-(tert-butyl)-6-(1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide -2-yl)-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutyramide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(6-cyano-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. The compounds described herein are effective for treating tuberous sclerosis (TS) / tuberous sclerosis complex (TSC). In embodiments, the subject is a pediatric subject.
[0121] In certain embodiments, administering a therapeutically effective amount of a compound of Table 1 or a pharmaceutically acceptable salt thereof can include administering about 0.1 mg to about 1,500 mg, about 1 mg to about 1,500 mg, about 10 mg to about 1,500 mg, about 50 mg to about 1,500 mg, about 75 mg to about 1,500 mg, about 100 mg to about 1,500 mg, about 125 mg to about 1,500 mg, about 150 mg to about 1,500 mg, about 175 mg to about 1,500 mg, about 200 mg to about 1,500 mg, about 225 mg to about 1,500 mg, about 250 mg to about 1,500 mg, about 275 mg to about 1,500 mg, about 300 mg to about 1,500 mg. In some embodiments, the present invention relates to a daily dosage of about 1,500 mg to about 1,500 mg, about 350 mg to about 1,500 mg, about 400 mg to about 1,500 mg, about 450 mg to about 1,500 mg, about 500 mg to about 1,500 mg, about 550 mg to about 1,500 mg, about 600 mg to about 1,500 mg, about 650 mg to about 1,500 mg, about 700 mg to about 1,500 mg, about 750 mg to about 1,500 mg, about 800 mg to about 1,500 mg, about 850 mg to about 1,500 mg, about 900 mg to about 1,500 mg, about 950 mg to about 1,500 mg, about 1,000 mg to about 1,500 mg, and about 1,200 mg to about 1,500 mg.
[0122] In certain embodiments, the therapeutically effective amount of a compound of Table 1, or a pharmaceutically acceptable salt thereof, is selected from about 0.1 mg to about 1,000 mg per day, about 50 mg to about 1,000 mg per day, about 100 mg to about 1,000 mg per day, about 150 mg to about 1,000 mg per day, about 300 mg to about 1,000 mg per day, about 50 mg to about 300 mg per day, and about 150 mg to about 300 mg per day.
[0123] This therapeutically effective amount can be administered once a day, or twice a day, three times a day, or four times a day in equal divided doses. In certain embodiments, the administration of a therapeutically effective amount includes twice a day administration equal to a dose of about half of the daily dose. In certain embodiments, the medicament is administered every about 12 hours. In certain embodiments, the administration of a therapeutically effective amount includes twice a day administration of about 1 mg, twice a day administration of about 5 mg, twice a day administration of about 10 mg, twice a day administration of about 25 mg, twice a day administration of about 75 mg, twice a day administration of about 150 mg, twice a day administration of about 300 mg, or twice a day administration of about 500 mg.
[0124] Pharmaceutical composition
[0125] Embodiments herein relate to pharmaceutical compositions comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3, 3-dimethylbutyramide; N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutyramide; N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide; N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-cyclobutyl- 7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. Pharmaceutical formulations containing such compounds and suitable carriers can take a variety of different forms, including, but not limited to, solids, solutions, powders, fluid emulsions, fluid suspensions, semisolids, and dry powders containing an effective amount of a compound of the invention. It is also known in the art that the active ingredient can be included in such preparations together with pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic carriers, water-soluble carriers, emulsifiers, buffers, wetting agents, humectants, solubilizers, antioxidants, preservatives, etc.Means and methods for administration are known in the art, and the skilled artisan can refer to various pharmacology references for guidance. For example, Modern Pharmaceutics, Banker & Rhodes, Marcel Dekker, Inc. (1979) and Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 6th edition, MacMillan Publishing Co., New York (1980), both of which are incorporated herein by reference in their entirety, can be consulted.
[0126] In certain embodiments, a single unit dose of a compound of Table 1 or a pharmaceutically acceptable salt thereof is selected from about 0.1 mg to about 1,500 mg, about 1 mg to about 1,500 mg, about 10 mg to about 1,500 mg, about 50 mg to about 1,500 mg, about 75 mg to about 1,500 mg, about 100 mg to about 1,500 mg, about 125 mg to about 1,500 mg, about 150 mg to about 1,500 mg, about 175 mg to about 1,500 mg, about 200 mg to about 1,500 mg, about 225 mg to about 1,500 mg. g to about 1,500 mg, about 250 mg to about 1,500 mg, about 275 mg to about 1,500 mg, about 300 mg to about 1,500 mg, about 400 mg to about 1,500 mg, about 450 mg to about 1,500 mg, about 500 mg to about 1,500 mg, about 600 mg to about 1,500 mg, about 700 mg to about 1,500 mg, about 800 mg to about 1,500 mg, about 1,000 mg to about 1,500 mg, and about 1,200 mg to about 1,500 mg.
[0127] In certain embodiments, a single unit dose of a compound of Table 1 or a pharmaceutically acceptable salt thereof is selected from about 25 mg to about 5,000 mg, about 50 mg to about 5,000 mg, about 100 mg to about 5,000 mg, about 150 mg to about 5,000 mg, about 200 mg to about 5,000 mg, about 250 mg to about 5,000 mg, about 300 mg to about 5,000 mg, about 400 mg to about 5,000 mg, about 450 mg to about 5,000 mg, about 100 mg to about 3,000 mg, about 150 mg to about 3,000 mg, about 200 mg to about 3 In some embodiments, the single unit dose may be 10 mg / day to 1,500 mg / day or about 100 mg / day to 600 mg / day. In some embodiments, such single unit dose may be administered once a day or multiple times a day, for example, twice a day or three times a day.
[0128] In certain embodiments, the single unit dosage further comprises a pharmaceutically acceptable carrier.
[0129] The compound can be formulated for parenteral or intravenous administration by injection, for example, by rapid bolus injection or continuous infusion. Injectable preparations can be present in unit dosage form, for example, in ampoules or multidose containers, with the addition of preservatives. The composition can take the form of a suspension, solution or emulsion, such as in an oily or aqueous vehicle, and can contain formulating agents such as suspending agents, stabilizers and / or dispersants.
[0130] Injectable preparations can be prepared according to known techniques using suitable dispersants or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions or suspensions in nontoxic parenterally acceptable diluents or solvents, for example as solutions in 1,3-butanediol. Acceptable carriers and solvents that can be used include water, Ringer's solution and isotonic sodium chloride solution.
[0131] Other embodiments include the compound prepared as described above, which is formulated into solid dosage forms for oral administration, including capsules, tablets, pills, powders and granules. In such embodiments, the active compound can be mixed with one or more inert diluents such as sucrose, lactose or starch. As in common practice, such dosage forms can also include other materials except inert diluents, such as lubricants such as magnesium stearate. In the case of capsules, tablets and pills, the dosage form can also include a buffer, and can be additionally prepared to have an enteric coating.
[0132] The compounds of the invention are prepared into solid dosage forms that can vary. For example, in one embodiment, a liquid or gelatin preparation can be prepared by merging compounds such as the compounds described above and adding a thickener to the liquid mixture to form gelatin. The gelatin can then be encapsulated in a unit dosage form to form a capsule. In another exemplary embodiment, the oily preparation of the compound prepared as described above can be lyophilized into a solid, which can be mixed with one or more pharmaceutically acceptable excipients, carriers or diluents to form a tablet.
[0133] Other embodiments that can be used for oral administration of the compounds of the present invention include liquid dosage forms. In such embodiments, liquid dosage forms can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water. Such compositions can also include adjuvants such as wetting agents, emulsifiers and suspending agents as well as sweeteners, flavoring agents and aromatics.
[0134] In other embodiments, the compounds described herein can be formulated into depot preparations. Such long-acting preparations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Depot injections can be administered at intervals of about 1 to about 6 months or longer. Therefore, for example, the compound can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or formulated into slightly soluble derivatives such as slightly soluble salts. Example
[0135] Example 1: Activation of KCNQ2
[0136] The M-current is described as a non-inactivating potassium current generated by the activation of Kv7 channels. The M-current is generated from the combination of two different Kv7 subunits that form heteromers. Kv7.3 can be combined with Kv7.2 or Kv7.5. In addition, Kv7 subunits can form functional homopolymers. The assembly of subunits into homopolymers or heteropolymers is believed to be based on the development and special regulation of expression. Importantly, heteropolymers have larger currents and significantly different permeability and conductivity properties compared to homopolymers. The data herein describe that compound A preferentially activates Kv7.2 compared to Kv7.2 / 7.3 or Kv7.3.
[0137] Bioassay Methods— Plasmids containing only wild-type (wt) KCNQ2, only wt KCNQ3, or both wt KCNQ2 and wt KCNQ3 subunits were expressed in Chinese hamster ovary (CHO) cells using lipid-mediated transfection. Gating and conductance density of wt channels were measured before, during, and after application of test compounds using a whole-cell voltage clamp protocol by local pipette perfusion. The half-activation voltage (V) was determined by Boltzmann fitting of the conductance-voltage (G / V) curves. 1 / 2 ).
[0138] Figure 1 Compound A (compounds described in Table 1) was confirmed to shift activation voltage dependence in cells. For KCNQ2 and KCNQ3 homomers and KCNQ2 / Q3 heteromers, Compound A shifted activation voltage dependence negatively in significant amounts. The magnitude of the shift depended on the KCNQ subunit composition, with KCNQ2>KCNQ2 / Q3>KCNQ3.
[0139] Figure 2 Compound A was confirmed to have the ability to activate Kv7.2 homomers. The current density from 3 μM compound A was significantly increased compared to the control. The current density activation caused by 3 μM compound A was similar to that produced by 10 μM ezagabine or ICA-069673. Example 2: Comparison of Compound A and Elzogabine in Homomeric and Heteromeric KCNQ2 Channels
[0140] Heterozygous KCNQ2 de novo variants (DNVs) are the cause of KCNQ2 epileptic encephalopathy (KCNQ2-EE). Most KCNQ2-EE variants are missense and clustered in hotspots, which are domains for key protein functions, namely voltage sensing, transmembrane ion flow, and sites regulating PIP2 and calmodulin binding. Under voltage clamp, many KCNQ2-EE DNVs act as dominant negatives when co-expressed with wild-type (wt) subunits to mimic heterozygosity. Ezogabine (EZO) increases current through channels containing mutant subunits in vitro and has been used in KCNQ2-EE patients. New small molecules that act as potent neuronal KCNQ channel openers are candidate precision medicines for KCNQ2-EE.
[0141] Four frequently occurring KCNQ2-EE missense variants ( Figure 3) R210H (located in S4 of the voltage sensor), T274M (located in the pore helix), A294V (located at the boundary of the pore loop and S6), and R581Q / L (located in the intracellular helix C) were introduced into the KCNQ2 cDNA. R210H is in S4 of the voltage sensor, T274M is in the pore helix, A294V is at the boundary of the pore loop and S6, and R581Q is in the intracellular helix C. Plasmids containing pathogenic variants were co-expressed with wild-type KCNQ2 or KCNQ2 and KCNQ3 subunits in Chinese hamster ovary (CHO) cells using lipid-mediated transfection. The KCNQ2 S5 helix mutation W236L, which abolished EZO regulation, was used to characterize compound A binding. Using a whole-cell voltage clamp protocol, gating and conductance of wild-type channels and channels containing mutant subunits were measured before, during, and after application of test compounds by local pipette perfusion.
[0142] Compound A increases the wild-type homopolymer ( Figure 4-6 ) and heteromers ( Figure 7-9 ) channel and shift its G / V curve. Figure 4 ) Compound A (0.3 μM and 1.0 μM) increased the homomeric channel density at -40 mV; ( Figure 5 )and( Figure 6 ) Compound A shifts the G / V curve of homopolymer KCNQ2 to the left. Figure 7 ) Representative currents recorded from cells expressing heteromeric wild-type KCNQ2 / KCNQ3 channels before and during application of 1.0 μM Compound A. ( Figure 8 )and( Fig. 9 ) Compound A left-shifted these heteromeric wild-type channels (N=3-10 cells; *<0.05, **<0.01, and ***<0.001).
[0143] Example 3: Comparison of Compound A with Elzogabine and ICA-069673 in Activation of KCNQ2 Homomers
[0144] Similar to EZO and unlike ICA-069673, Compound A activation of KCNQ2 homomers requires W236. Fig.10 , Fig.13 ) before and after drug administration, at -40 mV from cells expressing wild-type KCNQ2 ( Fig.10 ) and KCNQ2 W236L( Fig.13 Representative current traces recorded from cells with ). EZO and compound A increase the current density of wild-type KCNQ2 channels ( Fig.11 ), but does not affect the current density of the W236L channel ( Fig.14). G / V curves of hyperpolarization after drug administration (N=3-12 cells; *<0.05, **<0.01, and ***<0.001).
[0145] Example 4: Compound A stimulates the channel incorporating the common KCNQ2 voltage sensor domain pathogenic variant R210H live
[0146] Compound A activates channels incorporating the common KCNQ2 voltage sensor domain pathogenic variant R210H. Fig.18 ) Family of currents recorded from homomeric R210H channels before and after application of 1.0 μM Compound A. R210H activation was very strongly depolarizing; this effect was reversed by Compound A. ( Fig.19 ) Average current at +20 mV before and during application of Compound A. ( Fig. 20 ) Comparison of the effects of compound A on wild-type KCNQ2 and 1:1 co-expressed wild-type and R210H at -40 mV. ( Fig.21 , Fig. 22 ) Summary of the V1 / 2 shift of channels with different subunit combinations after application of 1.0 μM Compound A (N=6-19; *<0.05, **<0.01, and ***<0.001).
[0147] Example 5: Compound A Activation of Homomeric Channels Incorporated with Human KCNQ2 Variants
[0148] Compound A activates homomeric channels incorporating human pathogenic KCNQ2 variants (pore domain and C-terminus). Fig.23 ) Superimposed representative traces recorded at -40 mV from wild-type KCNQ2 and cells expressing 1:1 KCNQ2 and KCNQ2A294V before and during application of 0.3 μM Compound A. ( Fig.24 ) Summary of the effect of 0.3 μM Compound A on the current density of wild-type channels and channels formed by 1:1 co-expression of wild-type with the indicated pore domain and C-terminal variants (N=4-8; *<0.05, **<0.01, and ***<0.001). Example 6: Heteromeric proteins incorporating common pathogenic KCNQ2 variants T274M and A294V Compound A activation of the endosome channel
[0149] Compound A activated heteromeric channels incorporating common pathogenic KCNQ2 variants T274M and A294V (wild-type KCNQ2: variant: wild-type KCNQ3 cDNA ratio = 1:1:2 to simulate heterozygosity). Figure 25-27 ) and T274M( Figure 28-30Average current density, conductance / voltage curves, and V1 / 2 shifts of channels of ) at -40 mV (N=9-11; *<0.05, **<0.01, and ***<0.001).
[0150] Compound A activated KCNQ2-containing homomers and KCNQ2 / 3 heteromers by shifting activation and increasing maximal current. This KCNQ2 regulation required pore domain residue W236. Variants from three different KCNQ2-EE mutational hotspots showed strong dominant-negative current inhibition under conditions mimicking heterozygosity. Compound A (0.3–1 μM) increased currents in cells expressing each of these variants, raising currents to wild-type levels at -40 mV. These results suggest potential benefits in KCNQ2-EE.
[0151] The grouping of optional elements or embodiments disclosed herein should not be construed as limiting. Each group member can be quoted and claimed individually or in any combination with other members of the group or other elements found herein. For convenience and / or patentability reasons, it is expected that one or more members of a group may be included in a group or deleted from the group. When any such inclusion or deletion occurs, this specification is considered to include the modified group, thereby satisfying the written description of all Markush groups used in the accompanying claims.
[0152] Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations of these described embodiments will become apparent to those of ordinary skill in the art after reading the above description. The inventors expect that professionals and technicians will utilize such variations when appropriate, and the inventors intend to practice the invention in a manner different from that specifically described herein. Therefore, the claims include all modifications and equivalents of the subject matter recited in the claims as permitted by applicable law. In addition, unless otherwise specified herein or clearly contradictory to the context, any combination of the above elements in all possible variations thereof is contemplated.
[0153] Finally, it should be understood that the embodiments disclosed herein are illustrative of the principles of the claims. Other modifications that may be employed are within the scope of the claims. Therefore, by way of example and not limitation, alternative embodiments may be used in accordance with the teachings herein. Therefore, the claims are not limited to the embodiments precisely as shown and described herein.
Claims
1. Use of compound A or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a neurodevelopmental disease or disorder in a pediatric subject in need thereof, Wherein compound A or its pharmaceutically acceptable salt is selected from N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-4- Fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide; N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(7-cyano-1-(1-methyl N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-1-cyclobutyl-7-(trifluoromethyl)-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide )-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide; and N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide.
2. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide.
3. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-(tert-butyl)-6-(difluoromethoxy)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
4. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(6-cyano-1-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
5. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-cyclobutyl-4-fluoro-6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-(1-methylcyclopropyl)acetamide.
6. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(6-cyano-1-cyclobutyl-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
7. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-cyclobutyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
8. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-(tert-butyl)-6-cyano-4-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
9. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(7-cyano-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3-cyclopropyl-3-methylbutanamide.
10. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(6-chloro-7-cyano-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
11. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-cyclobutyl-5-fluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
12. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
13. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(6-cyano-1-cyclobutyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
14. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(6-cyano-4,7-difluoro-1-(1-methylcyclobutyl)-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.
15. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-(tert-butyl)-5,7-difluoro-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide.
16. The use according to claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is N-(1-(tert-butyl)-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide.
17. The method of claim 1, wherein the neurodevelopmental disease or disorder is selected from Angelman syndrome, neonatal abstinence syndrome, early myoclonic encephalopathy, Landau Kleffner syndrome, electrical status epilepticus during sleep, Ohtahara syndrome, autism spectrum disorder, Dravet syndrome, Lennox–Gastaut syndrome, Rett syndrome, infantile spasms (West syndrome), SCN8A-associated epilepsy with encephalopathy (EIEE13), infantile epilepsy with focal epilepsy (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Doose syndrome, adrenoleukodystrophy (ALD), ATP6V1A encephalopathy, atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant ADRESD, CDKL5 encephalopathy, childhood epilepsy with centrotemporal spikes (CECTS), epileptic encephalopathy with continuous spikes during sleep syndrome (ECSWS), GRIN1 encephalopathy, GRIN2A epilepsy-aphasia syndrome, GRIN2B encephalopathy, intermediate epilepsy-aphasia disorder (IEAD), infantile KCNT1 epilepsy with metastatic focal epilepsy, neuronal ceroid lipofuscinosis (NCL), nonsyndromic developmental and epileptic encephalopathy, PTPN23 encephalopathy, Rasmussen syndrome, SCN2A-related neonatal epilepsy, STXBP1 encephalopathy, tuberous sclerosis (TS) / tuberous sclerosis complex (TSC), and combinations thereof.
